Is Catalyst Pharmaceuticals Stock a Good Investment?
Catalyst Pharmaceuticals Investment Advice | CPRX |
- Examine Catalyst Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Catalyst Pharmaceuticals' leadership team and their track record. Good management can help Catalyst Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Catalyst Pharmaceuticals' business and its evolving consumer preferences.
- Compare Catalyst Pharmaceuticals' performance and market position to its competitors. Analyze how Catalyst Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Catalyst Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Catalyst Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Catalyst Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Catalyst Pharmaceuticals is a good investment.
Sell | Buy |
Strong Hold
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Catalyst Pharmaceuticals Stock
Researching Catalyst Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 83.0% of the company shares are held by institutions such as insurance companies. The book value of Catalyst Pharmaceuticals was currently reported as 6.02. The company had not issued any dividends in recent years.
To determine if Catalyst Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Catalyst Pharmaceuticals' research are outlined below:
| Catalyst Pharmaceuticals had very high historical volatility over the last 90 days | |
| Over 83.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: With 81 percent ownership in Catalyst Pharmaceuticals, Inc. , institutional investors have a lot riding on the business |
Catalyst Pharmaceuticals Quarterly Cash And Short Term Investments |
|
Catalyst Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Catalyst Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Catalyst Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Catalyst Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Catalyst Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-09 | 2021-06-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2020-11-09 | 2020-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2020-05-11 | 2020-03-31 | 0.09 | 0.1 | 0.01 | 11 | ||
2018-11-07 | 2018-09-30 | -0.07 | -0.08 | -0.01 | 14 | ||
2018-08-07 | 2018-06-30 | -0.07 | -0.06 | 0.01 | 14 | ||
2017-08-09 | 2017-06-30 | -0.06 | -0.05 | 0.01 | 16 | ||
2016-11-09 | 2016-09-30 | -0.06 | -0.05 | 0.01 | 16 | ||
2016-08-09 | 2016-06-30 | -0.07 | -0.06 | 0.01 | 14 |
Catalyst Pharmaceuticals Target Price Consensus
Catalyst target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Catalyst Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Strong Buy |
Most Catalyst analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Catalyst stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Catalyst Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCatalyst Pharmaceuticals Target Price Projection
Catalyst Pharmaceuticals' current and average target prices are 25.15 and 33.00, respectively. The current price of Catalyst Pharmaceuticals is the price at which Catalyst Pharmaceuticals is currently trading. On the other hand, Catalyst Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Catalyst Pharmaceuticals Market Quote on 26th of March 2025
Target Price
Analyst Consensus On Catalyst Pharmaceuticals Target Price
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Catalyst Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Catalyst Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Catalyst Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Know Catalyst Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Catalyst Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Catalyst Pharmaceuticals backward and forwards among themselves. Catalyst Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Catalyst Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Royce & Associates, Lp | 2024-12-31 | 1.9 M | Bank Of America Corp | 2024-12-31 | 1.6 M | Northern Trust Corp | 2024-12-31 | 1.5 M | Nuveen Asset Management, Llc | 2024-12-31 | 1.3 M | Boston Partners Global Investors, Inc | 2024-12-31 | 1.3 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.2 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.2 M | Kennedy Capital Management Inc | 2024-12-31 | 1 M | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 913 K | Blackrock Inc | 2024-12-31 | 19.4 M | Vanguard Group Inc | 2024-12-31 | 8.4 M |
Catalyst Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.13 B.Market Cap |
|
Catalyst Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.24 | 0.25 | |
| Return On Capital Employed | 0.27 | 0.28 | |
| Return On Assets | 0.19 | 0.20 | |
| Return On Equity | 0.23 | 0.24 |
Determining Catalyst Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Catalyst Pharmaceuticals is a good buy. For example, gross profit margin measures Catalyst Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Catalyst Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Catalyst Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Catalyst Pharmaceuticals. Check Catalyst Pharmaceuticals' Beneish M Score to see the likelihood of Catalyst Pharmaceuticals' management manipulating its earnings.
Evaluate Catalyst Pharmaceuticals' management efficiency
Catalyst Pharmaceuticals has return on total asset (ROA) of 0.1846 % which means that it generated a profit of $0.1846 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2938 %, meaning that it created $0.2938 on every $100 dollars invested by stockholders. Catalyst Pharmaceuticals' management efficiency ratios could be used to measure how well Catalyst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.25 in 2025. Return On Capital Employed is likely to rise to 0.28 in 2025. At this time, Catalyst Pharmaceuticals' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 654.8 M in 2025, whereas Other Assets are likely to drop 1.09 in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.14 | 6.45 | |
| Tangible Book Value Per Share | 4.82 | 5.06 | |
| Enterprise Value Over EBITDA | 10.03 | 10.53 | |
| Price Book Value Ratio | 3.40 | 3.23 | |
| Enterprise Value Multiple | 10.03 | 10.53 | |
| Price Fair Value | 3.40 | 3.23 | |
| Enterprise Value | 2 B | 2.1 B |
The strategic initiatives led by Catalyst Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 0.836 |
Basic technical analysis of Catalyst Stock
As of the 26th of March, Catalyst Pharmaceuticals shows the Mean Deviation of 2.14, risk adjusted performance of 0.0813, and Downside Deviation of 2.3. Catalyst Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Catalyst Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Catalyst Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Catalyst Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Catalyst Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Catalyst Pharmaceuticals' Outstanding Corporate Bonds
Catalyst Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Catalyst Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Catalyst bonds can be classified according to their maturity, which is the date when Catalyst Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Catalyst Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Catalyst Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0813 | |||
| Market Risk Adjusted Performance | 0.189 | |||
| Mean Deviation | 2.14 | |||
| Semi Deviation | 2.07 | |||
| Downside Deviation | 2.3 | |||
| Coefficient Of Variation | 1141.49 | |||
| Standard Deviation | 3.2 | |||
| Variance | 10.25 | |||
| Information Ratio | 0.0836 | |||
| Jensen Alpha | 0.2662 | |||
| Total Risk Alpha | 0.2598 | |||
| Sortino Ratio | 0.1165 | |||
| Treynor Ratio | 0.179 | |||
| Maximum Drawdown | 22.62 | |||
| Value At Risk | (3.27) | |||
| Potential Upside | 5.25 | |||
| Downside Variance | 5.28 | |||
| Semi Variance | 4.28 | |||
| Expected Short fall | (2.47) | |||
| Skewness | 2.18 | |||
| Kurtosis | 9.86 |
| Risk Adjusted Performance | 0.0813 | |||
| Market Risk Adjusted Performance | 0.189 | |||
| Mean Deviation | 2.14 | |||
| Semi Deviation | 2.07 | |||
| Downside Deviation | 2.3 | |||
| Coefficient Of Variation | 1141.49 | |||
| Standard Deviation | 3.2 | |||
| Variance | 10.25 | |||
| Information Ratio | 0.0836 | |||
| Jensen Alpha | 0.2662 | |||
| Total Risk Alpha | 0.2598 | |||
| Sortino Ratio | 0.1165 | |||
| Treynor Ratio | 0.179 | |||
| Maximum Drawdown | 22.62 | |||
| Value At Risk | (3.27) | |||
| Potential Upside | 5.25 | |||
| Downside Variance | 5.28 | |||
| Semi Variance | 4.28 | |||
| Expected Short fall | (2.47) | |||
| Skewness | 2.18 | |||
| Kurtosis | 9.86 |
Consider Catalyst Pharmaceuticals' intraday indicators
Catalyst Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Catalyst Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 53494.76 | |||
| Daily Balance Of Power | (0.61) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 25.49 | |||
| Day Typical Price | 25.38 | |||
| Price Action Indicator | (0.63) | |||
| Period Momentum Indicator | (0.57) | |||
| Relative Strength Index | 43.92 |
Catalyst Pharmaceuticals Corporate Filings
F4 | 7th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 28th of February 2025 Other Reports | ViewVerify | |
10K | 26th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 13th of February 2025 Other Reports | ViewVerify |
Catalyst Stock media impact
Far too much social signal, news, headlines, and media speculation about Catalyst Pharmaceuticals that are available to investors today. That information is available publicly through Catalyst media outlets and privately through word of mouth or via Catalyst internal channels. However, regardless of the origin, that massive amount of Catalyst data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Catalyst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Catalyst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Catalyst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Catalyst Pharmaceuticals alpha.
Catalyst Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Catalyst Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Catalyst Pharmaceuticals Historical Investor Sentiment
Investor biases related to Catalyst Pharmaceuticals' public news can be used to forecast risks associated with an investment in Catalyst. The trend in average sentiment can be used to explain how an investor holding Catalyst can time the market purely based on public headlines and social activities around Catalyst Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Catalyst Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Catalyst Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Catalyst Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals Corporate Management
| Philip Schwartz | Co Sec | Profile | |
| CMA CPA | VP, Officer | Profile | |
| Pete Sr | Vice Sales | Profile | |
| Mary Coleman | VP Relations | Profile | |
| Stanley MD | Senior Discovery | Profile | |
| Philip Esq | Corporate Secretary | Profile |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.